Bronchopulmonary Dysplasia Treatment Market
Rising cases of Respiratory Abnormalities in Infants to spur treatment for Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia Treatment Market by Drug Type, Therapy, End User & Region - Forecast 2022 - 2032
Bronchopulmonary Dysplasia Treatment Market Snapshot (2022-2032)
[308 Pages Report] The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 346 Million in 2022 and is expected to accumulate US$ 661.7 Million by registering a CAGR of 6.1% in the forecast period 2022-2032. Growth of the bronchopulmonary dysplasia treatment market can be attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe. The market for bronchopulmonary dysplasia treatment registered a CAGR of 5.9% in the historical period 2016-2021.
|
Data Points |
Key Statistics |
|
Estimated Base Year Value (2021) |
US$ 344.98 Million |
|
Expected Market Value (2022) |
US$ 346 Million |
|
Anticipated Forecast Value (2032) |
US$ 661.7 Million |
|
Projected Growth Rate (2022-2032) |
6.1% CAGR |
Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection.
Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition can cause serious complications during infancy and might requires hospitalization and intensive medical care, during the first 2 years after birth.
The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.
The disease can cause from other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, that affects the development of the lungs.
Let us know your requirement to get
100% FREE customization
2016-2021 Bronchopulmonary Dysplasia Treatment Demand Analysis vs. Forecast 2022-2032
The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period between 2022 and 2032, reaching a total of US$ 661.7 Million in 2032, according to a report from Future Market Insights (FMI). From 2016 to 2021, sales witnessed significant growth, registering a CAGR of 5.9%.
The prevalence of COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.
Furthermore, most end user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favouring the growth of the market in the assessment period 2022-2032.
Which are Some Prominent Drivers of Bronchopulmonary Dysplasia Treatment Market?
Premature births creating opportunities for bronchopulmonary dysplasia treatment
According to the Airway estimates, in Europe and the U.S. up to 160,000 infants are at highest risk for the development of BPD collectively, each year. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of bronchopulmonary dysplasia treatment market over the forecast period.
Growing research and development activities by pharmaceutical companies to develop innovative treatment option for bronchopulmonary dysplasia would boost the market in near future.
Research and treatment options contributing to market growth
Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.
On the other hand, research is developing stem cell therapy for novel therapeutic modality for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in the preterm infants.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Bronchopulmonary Dysplasia Treatment Market?
Lack of awareness along with undiagnosed infants derailing growth
Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles for market growth. Moreover, high cost of treatment owing to the complex nature of the disease is another factor is impeding the market growth.
Furthermore, lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of bronchopulmonary dysplasia treatment market.
Technological Advancements Creating Lucrative Opportunities for Bronchopulmonary Dysplasia Treatment Market in North America?
High treatment rate enhcaing growth of market
North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased in awareness about the bronchopulmonary dysplasia, and high treatment rate are expected to drive the growth of the market over the forecast period.
Advancements in the healthcare sector along with continuous research and development in for treating bronchopulmonary dysplasia is favoring the market growth especially in the U.S. Thus, due to the reasons mentioned above, North America is expected to hold 41.2% market share for bronchopulmonary dysplasia treatment market in 2022.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Increasing Deaths of Infants Bolstering Early Diagnosis of Bronchopulmonary Dysplasia Treatment Market in Europe?
Undiagnosed cases alarming healthcare professionals to take action
Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region. In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.
The strong presence of healthcare sectors in Netherlands along with government policies working in the favor of childcare are accelerating the growth of the bronchopulmonary dysplasia treatment market Thus, owing to the aforementioned reasons, Europe is expected to possess 37.2% market share for bronchopulmonary dysplasia treatment market in 2022.
Increasing Awareness and Favorable Policies Accelerating Growth of Bronchopulmonary Dysplasia Treatment Market in Asia Pacific?
Growth of preterm rate and government initiatives boosting dependency on treatment
With 73.6 million live births in Asia Pacific and a preterm rate <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown overtime. Rise in awareness toward treatment of the disease, and increase in health care expenditure are expected to boost the growth of the bronchopulmonary dysplasia treatment market growth.
Large patient pool along with government programs and initiatives are the key factors influencing the growth of the bronchopulmonary dysplasia treatment market in Asia Pacific. Thus, Asia Pacific is expected to procure 35% market share for bronchopulmonary dysplasia treatment market in 2022.
Category-Wise Insights
Effectiveness of Supplemental Oxygen Therapy a Dependable Treatment Option for Bronchopulmonary Dysplasia Treatment?
Safety of infants increasing reliability on supplemental oxygen therapy
The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as effectiveness of drugs and more commonly used therapy.
In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy is expected to hold 35% market share for bronchopulmonary dysplasia treatment market in 2022.
Availability of Different Treatments Making Hospitals a Feasible Option for Bronchopulmonary Dysplasia Treatment Market?
Immediate diagnosis and treatments making hospitals reliable
Based on end-user, the global bronchopulmonary dysplasia treatment market can be classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.
Moreover, most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals are expected to possess 40% market share for bronchopulmonary dysplasia treatment market in 2022.
Start-Ups in the Bronchopulmonary Dysplasia Treatment Market
Key start- up players in the bronchopulmonary dysplasia treatment market are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.
- In May 2022, AyuVis secured $1.8 Million through Small Business Innovation Research Grant to support the research of its investigational product (AVR-48) targeting bronchopulmonary dysplasia treatment market.
- Altavant, a key start-up in the bronchopulmonary dysplasia treatment market is focusing on creating small molecule inhibitors for respiratory disorders.
Market Competition
Some of the players in global bronchopulmonary dysplasia treatment market include Airway Therapeutics LLC, Chiesi Farmaceutici SpA, Insmed Incorporated, MediPost Co., Ltd., Meridigen Biotech Co., Ltd, Syntrix Biosystems, Inc., Therabron Therapeutics and others.
- In March 2022, Airway Therapeutics LLC announced dosing of the first patient in the Phase 1b randomized trial AT-100 (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). The clinical trial of the drug is expected to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
- Chiesi Farmaceutici SpA, a key player in the bronchopulmonary dysplasia treatment market is focusing on research for newer treatments and effective drugs that will increase recovery rate and reduce pain.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2022 |
US$ 346 Million |
|
Market Value in 2032 |
US$ 661.7 Million |
|
Growth Rate |
CAGR of 6.1% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Bronchopulmonary Dysplasia Treatment Market Industry Survey
Bronchopulmonary Dysplasia Treatment Market by Drug Type:
- Bronchopulmonary Dysplasia Treatment by Bronchodilators
- Bronchopulmonary Dysplasia Treatment by Diuretics
- Bronchopulmonary Dysplasia Treatment by Antibiotics
- Bronchopulmonary Dysplasia Treatment by Steroids
- Bronchopulmonary Dysplasia Treatment by Immunomodulators
- Bronchopulmonary Dysplasia Treatment by Surfactant Homeostasis
Bronchopulmonary Dysplasia Treatment Market by Therapy Type:
- Bronchopulmonary Dysplasia Treatment by Nitric Oxide Therapy
- Bronchopulmonary Dysplasia Treatment by Protein replacement therapy
- Bronchopulmonary Dysplasia Treatment by Stem Cell Therapy
- Bronchopulmonary Dysplasia Treatment by Supplemental Oxygen
Bronchopulmonary Dysplasia Treatment Market by End User:
- Bronchopulmonary Dysplasia Treatment by Hospitals
- Bronchopulmonary Dysplasia Treatment by Nursing Homes
- Bronchopulmonary Dysplasia Treatment by Critical Care Centers
Bronchopulmonary Dysplasia Treatment Market by Region:
- North America Bronchopulmonary Dysplasia Treatment Market
- Latin America Bronchopulmonary Dysplasia Treatment Market
- Europe Bronchopulmonary Dysplasia Treatment Market
- Asia Pacific Bronchopulmonary Dysplasia Treatment Market
- Middle East & Africa Bronchopulmonary Dysplasia Treatment Market
Frequently Asked Questions
FMI projects the global bronchopulmonary dysplasia treatment market to expand at a 6.1% value CAGR by 2032
The global bronchopulmonary dysplasia treatment market is estimated at a market value of US$ 346 Million
The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 661.7 Million
North America is expected to hold 41.2% market share for bronchopulmonary dysplasia treatment market in 2022.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2016-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032
5.3.1. Bronchodilators
5.3.2. Diuretics
5.3.3. Antibiotics
5.3.4. Steroids
5.3.5. Immunomodulators
5.3.6. Surfactant Homeostasis
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2016-2021
5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032
6. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Therapy Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2016-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032
6.3.1. Nitric Oxide Therapy
6.3.2. Protein Replacement Therapy
6.3.3. Stem Cell Therapy
6.3.4. Supplemental Oxygen
6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2016-2021
6.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032
7. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Nursing Homes
7.3.3. Critical Care Centers
7.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
8. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. US
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Therapy Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Therapy Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Therapy Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Therapy Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Type
11.2.3. By Therapy Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Therapy Type
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Drug Type
12.2.3. By Therapy Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Therapy Type
12.3.4. By End User
12.4. Key Takeaways
13. MEA Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Type
13.2.3. By Therapy Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Therapy Type
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Bronchopulmonary Dysplasia Treatment Market Analysis
14.1. US
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Drug Type
14.1.2.2. By Therapy Type
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Drug Type
14.2.2.2. By Therapy Type
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Drug Type
14.3.2.2. By Therapy Type
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Drug Type
14.4.2.2. By Therapy Type
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Drug Type
14.5.2.2. By Therapy Type
14.5.2.3. By End User
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Drug Type
14.6.2.2. By Therapy Type
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Drug Type
14.7.2.2. By Therapy Type
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Drug Type
14.8.2.2. By Therapy Type
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Drug Type
14.9.2.2. By Therapy Type
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Drug Type
14.10.2.2. By Therapy Type
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Drug Type
14.11.2.2. By Therapy Type
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Drug Type
14.12.2.2. By Therapy Type
14.12.2.3. By End User
14.13. GCC Countries
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Drug Type
14.13.2.2. By Therapy Type
14.13.2.3. By End User
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Drug Type
14.14.2.2. By Therapy Type
14.14.2.3. By End User
14.15. Israel
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Drug Type
14.15.2.2. By Therapy Type
14.15.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Type
15.3.3. By Therapy Type
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Airway Therapeutics LLC
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Chiesi Farmaceutici
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Insmed Incorporated
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. MediPost
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Meridigen Biotech
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Syntrix Biosystems
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Martindale Pharmaceuticals
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Takeda
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Oak Hill Bio
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Mallinckrodt
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. AdventHealth
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Region, 2016-2032
Table 2: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 3: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 4: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 5: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 6: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 7: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 8: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 9: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 10: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 11: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 12: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 13: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 14: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 15: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 16: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 17: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 18: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 19: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 20: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 21: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 22: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032
Table 23: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032
Table 24: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 2: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 3: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 4: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Region, 2016-2032
Figure 6: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 9: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 10: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 11: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 12: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 13: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 14: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 15: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 16: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 17: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 18: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 19: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 20: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Region, 2022-2032
Figure 21: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 22: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 23: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 24: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 26: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 29: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 30: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 31: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 32: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 33: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 34: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 35: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 36: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 37: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 38: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 39: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 40: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 42: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 43: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 44: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 46: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 49: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 50: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 51: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 52: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 53: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 54: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 55: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 56: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 57: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 58: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 59: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 60: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032
Figure 61: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 62: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 63: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 64: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 66: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 69: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 70: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 71: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 72: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 73: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 74: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 75: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 76: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 77: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 78: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 79: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 80: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 82: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 83: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 84: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 86: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 89: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 90: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 91: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 92: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 93: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 94: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 95: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 96: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 97: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 98: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 99: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 100: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032
Figure 101: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 102: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 103: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032
Figure 104: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 106: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032
Figure 109: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 110: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 111: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032
Figure 112: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 113: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 114: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 115: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 116: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 117: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032
Figure 118: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032
Figure 119: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032
Figure 120: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
